Abstract
Disease heterogenicity among Ulcerative colitis (UC) patients and their variable responses to therapy is not well understood. Previously, using publicly available transcriptomes from colonic tissue of UC patients, we demonstrated the immune cell landscape and pathways that are common and distinct among patients and for non-responders to biologic therapy. Here, we AIM to determine differentially expressed gene signatures specific to inflamed UC tissue and for non-responders to biologic anti-TNFa and anti-a4b7 therapy in large patient cohorts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
